US Patent

US9657003 — Androgen receptor modulating compounds

Method of Use · Assigned to Orion Oyj · Expires 2030-10-27 · 4y remaining

Vulnerability score 51/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects compounds of formula (I) and their pharmaceutically acceptable salts, as well as compositions and methods of treating with them.

USPTO Abstract

The present disclosure relates to compounds of formula (I), and pharmaceutically acceptable salts thereof. The present disclosure also relates to compositions and methods of treating comprising compounds of formula (I), and pharmaceutically acceptable salts thereof.

Drugs covered by this patent

Nubeqa (darolutamide) · Bayer

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-4209`	—	Nubeqa

Patent Metadata

Patent number: US9657003
Jurisdiction: US
Classification: Method of Use
Expires: 2030-10-27
Drug substance claim: Yes
Drug product claim: Yes
Assignee: Orion Oyj
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.